INDIANAPOLIS, June 25,
2024 /PRNewswire/ -- Eli Lilly and Company (NYSE:
LLY) announced a collaboration with OpenAI that will allow Lilly to
leverage OpenAI's generative AI to invent novel antimicrobials to
treat drug-resistant pathogens. Antimicrobial resistance (AMR) is
one of the top public health and development threats across the
global health landscape.
"Our collaboration with OpenAI represents a groundbreaking step
forward in the fight against the growing but overlooked threat of
antimicrobial resistance," said Diogo
Rau, executive vice president and chief information and
digital officer at Lilly. "Generative AI opens a new opportunity to
accelerate the discovery of novel antimicrobials and the
development of custom, purpose-built technologies in the battle
against drug-resistant pathogens. This partnership underscores our
commitment to addressing significant health challenges experienced
by people around the world."
AMR affects countries in all regions and at all income levels
and is exacerbated by poverty and inequality, particularly in low-
and middle-income countries, which results in the greatest impact
and risk. The misuse and overuse of antimicrobials in humans,
animals and plants are the main drivers in the development of
drug-resistant pathogens, magnifying this threat to global
health.
"We're excited to work with Lilly to find new ways to treat
microbial infections," said Brad
Lightcap, chief operating officer at OpenAI. "Advanced AI
has the potential to deliver innovative breakthroughs in pharma,
and we're committed to working together with industry leaders to
deliver tangible benefits for patients."
This collaboration with OpenAI supports Lilly's earlier
commitment to fighting drug-resistant pathogens through its Social
Impact Venture Capital Portfolio. In 2020, the portfolio committed
$100 million to the AMR Action
Fund, aiming to provide patients with two to four new antibiotics
by 2030 and contribute the next line of defense against
multi-drug-resistant pathogens. In April 2023, the AMR
Action Fund announced its latest investments in biotech
companies targeting a range of infections.
About Lilly
Lilly is a medicine company turning
science into healing to make life better for people around the
world. We've been pioneering life-changing discoveries for nearly
150 years, and today our medicines help more than 51 million people
across the globe. Harnessing the power of biotechnology, chemistry
and genetic medicine, our scientists are urgently advancing new
discoveries to solve some of the world's most significant health
challenges: redefining diabetes care; treating obesity and
curtailing its most devastating long-term effects; advancing the
fight against Alzheimer's disease; providing solutions to some of
the most debilitating immune system disorders; and transforming the
most difficult-to-treat cancers into manageable diseases. With each
step toward a healthier world, we're motivated by one thing: making
life better for millions more people. That includes delivering
innovative clinical trials that reflect the diversity of our world
and working to ensure our medicines are accessible and affordable.
To learn more, visit Lilly.com and Lilly.com/news, or follow
us on Facebook, Instagram and LinkedIn. C-LLY
Cautionary Statement Regarding Forward-Looking
Statements
This press release contains forward-looking
statements (as that term is defined in the Private Securities
Litigation Reform Act of 1995) about the benefits of a
collaboration between Lilly and OpenAI, Lilly's research and
development strategy, and potential payments to OpenAI in
connection with the collaboration and reflects Lilly's current
beliefs and expectations. However, as with any such undertaking,
there are substantial risks and uncertainties in the process of
drug research, development and commercialization. Among other
things, there can be no guarantee that Lilly will realize the
expected benefits of the collaboration, that the collaboration will
yield commercially successful products, or that Lilly will execute
its strategy as expected. For further discussion of these and other
risks and uncertainties that could cause actual results to differ
from Lilly's expectations, see Lilly's Form 10-K and Form 10-Q
filings with the United States Securities and Exchange Commission.
Except as required by law, Lilly undertakes no duty to update
forward-looking statements to reflect events after the date of this
release.
Refer
to:
|
Jordan Bishop;
jordan.bishop@lilly.com; 317-473-5712 (Media)
|
|
Joe
Fletcher; jfletcher@lilly.com; 317-296-2884
(Investors)
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/lilly-collaborates-with-openai-to-discover-novel-medicines-to-treat-drug-resistant-bacteria-302180973.html
SOURCE Eli Lilly and Company